8-K: OrthoPediatrics Posts Record 2025 Revenue, Strong Q4 Cash Flow

OrthoPediatrics Corp. announced record full year 2025 revenue of $236.3 million, a 15% increase, alongside significant Q4 free cash flow generation and positive 2026 guidance.

Summary

• Generated record total annual revenue of $236.3 million for full year 2025, up 15% from $204.7 million in 2024.
• Achieved total revenue of $61.6 million for fourth quarter 2025, up 17% from $52.7 million in fourth quarter 2024.
• Operating cash flow improved by $22 million in full year 2025.
• Generated $9.8 million of free cash flow in the fourth quarter, marking the first quarter of positive free cash flow in company history.
• Achieved record full year adjusted EBITDA of $14.8 million in 2025, compared to $8.5 million in 2024.
• Reported adjusted EBITDA of $4.8 million in the fourth quarter of 2025, compared to $3.0 million in the fourth quarter of 2024.
• Helped over 37,500 children in Q4 2025 and approximately 151,000 for full year 2025, bringing the total to over 1.3 million since inception.
• Reiterated full year 2026 revenue guidance to be in a range of $262.0 million to $266.0 million, representing growth of 11% to 13% compared to 2025.
• Provided full year 2026 guidance for adjusted EBITDA of $25 million and breakeven free cash flow.
• Gross profit margin for the fourth quarter of 2025 was 73.2%, compared to 67.5% for the same period last year.
• Gross profit margin for the full year 2025 was 73.1%, compared to 72.6% in 2024.
• Net loss for the fourth quarter of 2025 was $10.1 million, compared to $16.1 million for the same period last year.
• Net loss for the full year 2025 was $39.6 million, compared to a net loss of $37.8 million last year.
• Cash and cash equivalents, short-term investments and restricted cash were $62.9 million as of December 31, 2025, compared to $70.8 million as of December 31, 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, highlighting significant operational improvements, record revenue growth, and the achievement of positive free cash flow for the first time, coupled with optimistic 2026 guidance. While full-year net loss increased, the underlying operational metrics and forward-looking statements are highly positive.

Positives

• Achieved record full year 2025 revenue of $236.3 million, a 15% increase over 2024.
• Reported strong fourth quarter 2025 revenue growth of 17% to $61.6 million.
• Generated $9.8 million of free cash flow in Q4 2025, marking the first quarter of positive free cash flow in company history.
• Operating cash flow improved by $22 million in full year 2025.
• Achieved record full year adjusted EBITDA of $14.8 million in 2025, a significant increase from $8.5 million in 2024.
• Net loss for Q4 2025 significantly improved to $10.1 million, compared to $16.1 million in Q4 2024.
• Gross profit margin increased for both Q4 2025 (73.2% vs 67.5%) and full year 2025 (73.1% vs 72.6%).
• Domestic revenue increased 16% for the full year and 13% in Q4 2025.
• International revenue increased 15% for the full year and a strong 33% in Q4 2025.
• Trauma, Deformity, and Scoliosis implant businesses continued to gain market share and improve profitability.
• Specialty bracing business (OPSB) is performing ahead of expectations and deepening customer relationships.
• Provided positive 2026 guidance for revenue ($262.0M-$266.0M), adjusted EBITDA ($25M), and breakeven free cash flow.
• Supported care for over 1.3 million children since inception.

Negatives

• Full year 2025 net loss increased to $39.6 million from $37.8 million in 2024.
• Net loss per share for full year 2025 increased to $1.69 from $1.64 in 2024.
• Cash and cash equivalents, short-term investments and restricted cash decreased to $62.9 million as of December 31, 2025, from $70.8 million as of December 31, 2024.
• Sports Medicine/Other revenue decreased 10% for full year 2025 to $4.0 million.
• General and administrative expenses increased 22.6% to $30.0 million in Q4 2025 and 16.6% to $119.8 million for full year 2025, driven by personnel, OPSB expansion, and non-cash items.
• An intangible asset impairment charge of $4.6 million was recorded in 2025, up from $1.8 million in 2024.

Risks

• Impact of widespread health emergencies, such as COVID-19 and respiratory syncytial virus.
• Other known and unknown risks, uncertainties, and factors detailed in OrthoPediatrics' Annual Report on Form 10-K filed with the SEC on March 5, 2025, as updated and supplemented by other SEC reports.

Future Outlook

The company expects full year 2026 revenue to be in the range of $262.0 million to $266.0 million, representing growth of 11% to 13% over 2025. It also anticipates generating approximately $25.0 million of adjusted EBITDA and achieving breakeven free cash flow in 2026, alongside an annual set deployment of approximately $10.0 million. Management is confident in executing long-term objectives due to a 'super cycle of innovative new product launches' and diversified growth drivers.

Management Comments

• "In 2025, we delivered strong operational execution, advanced our strategic priorities, and further solidified our leadership in pediatric orthopedics."
• "Our Trauma, Deformity, and Scoliosis implant businesses continued to gain market share, support revenue growth, and improve profitability, while our specialty bracing business remains a compelling, capital-efficient growth platform that is deepening customer relationships and performing ahead of our expectations."
• "In the fourth quarter alone, we supported care for more than 37,500 children, bringing our total impact to more than 1.3 million since inception."
• "We also generated significant free cash flow in the fourth quarter that highlights the strength of our business model and our path to achieve cash flow breakeven in 2026."
• "As we look ahead, we are entering a super cycle of innovative new product launches that increases our confidence that our diversified growth drivers and disciplined operating approach will enable us to execute on our long-term objectives and continue delivering meaningful impact for children worldwide."

Industry Context

StockSavvy.ai notes that OrthoPediatrics' exclusive focus on pediatric orthopedics positions it uniquely in a specialized niche. The strong growth in core implant businesses (Trauma, Deformity, Scoliosis) and the outperformance of the specialty bracing business (OPSB) suggest effective market penetration and product strategy within this segment. The emphasis on new product launches aligns with broader medical device industry trends of continuous innovation to drive growth and maintain competitive advantage, particularly in specialized markets with unmet needs.

Stakeholder Impact

• Shareholders: Potential positive impact due to strong financial performance, record revenue, improved profitability, and positive future guidance, which could lead to increased share value.
• Customers (Children/Patients): Positive impact as the company helped over 151,000 children in 2025 and plans for a 'super cycle of innovative new product launches' to improve lives.
• Employees: Potential positive impact from company growth and expansion, particularly in the OPSB business which led to increased personnel.
• Creditors: Improved operating cash flow and a path to breakeven free cash flow in 2026 suggest improved financial health and ability to meet obligations.

Next Steps

• Host a conference call on February 26, 2026, at 4:30 p.m. ET to discuss the results.
• Enter a 'super cycle of innovative new product launches' to drive future growth.
• Work towards achieving cash flow breakeven in 2026.
• Execute on long-term objectives to continue delivering meaningful impact for children worldwide.

Key Dates

Recommendation

The company demonstrated robust financial performance with record revenue, significant adjusted EBITDA growth, and a pivotal achievement of positive free cash flow in Q4 2025. The strong 2026 guidance, including projected breakeven free cash flow and continued revenue growth, indicates a clear path to sustained profitability and operational efficiency. These factors, combined with market share gains in core segments and a pipeline of new product launches, suggest strong future potential for investors.

Keywords

Pediatric orthopedics, medical devices, surgical systems, trauma, deformity, scoliosis, sports medicine, financial results, earnings, revenue, EBITDA, cash flow, Nasdaq